11
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      The transcription factor E4F1 coordinates CHK1-dependent checkpoint and mitochondrial functions.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Recent data support the notion that a group of key transcriptional regulators involved in tumorigenesis, including MYC, p53, E2F1, and BMI1, share an intriguing capacity to simultaneously regulate metabolism and cell cycle. Here, we show that another factor, the multifunctional protein E4F1, directly controls genes involved in mitochondria functions and cell-cycle checkpoints, including Chek1, a major component of the DNA damage response. Coordination of these cellular functions by E4F1 appears essential for the survival of p53-deficient transformed cells. Acute inactivation of E4F1 in these cells results in CHK1-dependent checkpoint deficiency and multiple mitochondrial dysfunctions that lead to increased ROS production, energy stress, and inhibition of de novo pyrimidine synthesis. This deadly cocktail leads to the accumulation of uncompensated oxidative damage to proteins and extensive DNA damage, ending in cell death. This supports the rationale of therapeutic strategies simultaneously targeting mitochondria and CHK1 for selective killing of p53-deficient cancer cells.

          Related collections

          Author and article information

          Journal
          Cell Rep
          Cell reports
          Elsevier BV
          2211-1247
          Apr 14 2015
          : 11
          : 2
          Affiliations
          [1 ] Equipe labellisée Ligue Contre le Cancer, Institut de Génétique Moléculaire de Montpellier, UMR5535, Centre National de la Recherche Scientifique (CNRS), 34293 Montpellier, France; Institut de Recherche en Cancérologie de Montpellier (IRCM), 34298 Montpellier, France; Institut National de la Santé et de la Recherche Médicale (INSERM), U1194, 34298 Montpellier, France; Université de Montpellier, 34090 Montpellier, France; Institut régional du Cancer de Montpellier, 34298 Montpellier, France. Electronic address: genevieve.rodier@inserm.fr.
          [2 ] Equipe labellisée Ligue Contre le Cancer, Institut de Génétique Moléculaire de Montpellier, UMR5535, Centre National de la Recherche Scientifique (CNRS), 34293 Montpellier, France; Université de Montpellier, 34090 Montpellier, France.
          [3 ] Sorbonne Universités, UPMC Univ Paris 06, UMR 8256, Biological Adaptation and Ageing-IBPS, 75005 Paris, France.
          [4 ] Equipe labellisée Ligue Contre le Cancer, Institut de Génétique Moléculaire de Montpellier, UMR5535, Centre National de la Recherche Scientifique (CNRS), 34293 Montpellier, France; Institut de Recherche en Cancérologie de Montpellier (IRCM), 34298 Montpellier, France; Institut National de la Santé et de la Recherche Médicale (INSERM), U1194, 34298 Montpellier, France; Université de Montpellier, 34090 Montpellier, France; Institut régional du Cancer de Montpellier, 34298 Montpellier, France.
          [5 ] Institut de Recherche en Cancérologie de Montpellier (IRCM), 34298 Montpellier, France; Institut National de la Santé et de la Recherche Médicale (INSERM), U1194, 34298 Montpellier, France; Université de Montpellier, 34090 Montpellier, France; Institut régional du Cancer de Montpellier, 34298 Montpellier, France.
          [6 ] MGX-Montpellier GenomiX, c/o Institut de Génomique Fonctionnelle, 141 rue de la cardonille, 34094 Cedex 5 Montpellier, France.
          [7 ] Sorbonne Universités, UPMC Univ Paris 06, UMR 8256, Biological Adaptation and Ageing-IBPS, 75005 Paris, France; INSERM U1164, 75005 Paris, France.
          [8 ] Institut de Recherche en Cancérologie de Montpellier (IRCM), 34298 Montpellier, France; Institut National de la Santé et de la Recherche Médicale (INSERM), U1194, 34298 Montpellier, France; Université de Montpellier, 34090 Montpellier, France; Institut régional du Cancer de Montpellier, 34298 Montpellier, France. Electronic address: laurent.lecam@inserm.fr.
          [9 ] Equipe labellisée Ligue Contre le Cancer, Institut de Génétique Moléculaire de Montpellier, UMR5535, Centre National de la Recherche Scientifique (CNRS), 34293 Montpellier, France; Institut de Recherche en Cancérologie de Montpellier (IRCM), 34298 Montpellier, France; Institut National de la Santé et de la Recherche Médicale (INSERM), U1194, 34298 Montpellier, France; Université de Montpellier, 34090 Montpellier, France; Institut régional du Cancer de Montpellier, 34298 Montpellier, France. Electronic address: claude.sardet@inserm.fr.
          Article
          S2211-1247(15)00293-4
          10.1016/j.celrep.2015.03.024
          25843721
          a89f88e1-0119-4bbb-a224-18244533eea0
          Copyright © 2015 The Authors. Published by Elsevier Inc. All rights reserved.
          History

          Comments

          Comment on this article